The firm aims to seek accelerated FDA approval for the test. Credit: Elchinator from Pixabay.

Tesis Biosciences has developed a new test to detect genetic mutations which are anticipated to pose more risk to individuals from the Covid-19 virus.

The company has already initiated the process of obtaining a patent for this assay. It also intends to seek accelerated US Food and Drug Administration (FDA) approval for the test before the onset of summer.

Related Company Profiles

View all

Tesis Biosciences chief research officer Divyen Patel said: “This new test uses data from more than 50 studies conducted by scientists worldwide and is a groundbreaking advancement in our understanding of why some people are more impacted by Covid-19 than others.

“It will become an important tool in our campaign to better understand and control this horrible disease.

“Even without knowing the exact relationship between the mutations and severe Covid-19 response, the test can identify and protect those in the greatest danger.”

See Also:

In contrast to prior investigations that focused on a limited set of genes, the Tesis genome-wide association study analysed all 3.2bn DNA base pairs to detect all factors that influence outcomes.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The company has found that around 60 specific single nucleotide polymorphisms are linked to cases of Covid-19 resulting in death or severe illness.

After years of extensive research, the mutations that Tesis has complied with are anticipated to be present in 1-3% of the population. However, this percentage may vary as further screening takes place.

While the exact connection between these mutations and Covid-19 infections remains not fully understood, all the mutations are linked to genes responsible for the body’s early response to an initial infection.